Results 161 to 170 of about 691,066 (375)

Pharmacokinetics and pharmacodynamics of empagliflozin in paediatric patients aged 10–17 years with type 2 diabetes mellitus

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims To characterize the pharmacokinetics (PK) and PK/pharmacodynamics (PD) regarding glycosylated haemoglobin (HbA1c) lowering using the paediatric data from DINAMO and to assess differences compared with adults. Methods Population PK and PK/PD models previously developed for empagliflozin in adults and adolescents were re‐estimated in a Bayesian ...
Juliane Rascher   +7 more
wiley   +1 more source

Population pharmacokinetic modelling of prednisolone in systemic lupus erythematosus patients: Analysis of exposure and disease activity

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Prednisone is a widely used glucocorticoid in the treatment of lupus, although its dosing is often determined empirically. Prednisolone, the active metabolite of prednisone, is found in its free form in the serum. The goal of this study was to develop a population pharmacokinetic model in patients with systemic lupus erythematosus (SLE ...
Naïm Bouazza   +26 more
wiley   +1 more source

Role of the Innate Immune Response in Glomerular Disease Pathogenesis: Focus on Podocytes

open access: yesCells
Accumulating evidence indicates that inflammatory and immunologic processes play a significant role in the development and progression of glomerular diseases.
Wadih Issa   +4 more
doaj   +1 more source

Population pharmacokinetics and optimized dosing of cefuroxime in critically ill patients

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Cefuroxime is a second‐generation cephalosporin widely used in the intensive care unit (ICU). ICU patients have high variability in interpatient pharmacokinetics (PK), but the extent of this variation is unclear. We performed an observational PK study in ICU patients.
Jaap W. A. Mouton   +9 more
wiley   +1 more source

Probability of pharmacokinetic/pharmacodynamic target attainment for different piperacillin/tazobactam dosing regimens in renally impaired patients in a non‐intensive care unit setting

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims To optimize antibiotic therapy for pathogens classified as susceptible, increased exposure (I), an increased exposure of piperacillin/tazobactam (PTZ) is required. However, dosing recommendations are currently only available for patients with normal renal function.
Emma Dohmann   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy